- Home
- ASND vs SNN Comparison
ASND vs SNN Comparison
Compare ASND & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASND | SNN |
|---|---|---|
| Founded | 2006 | 1856 |
| Country | Denmark | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.6B | 14.3B |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | ASND | SNN |
|---|---|---|
| Price | $228.00 | $32.11 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 16 | 2 |
| Target Price | ★ $279.50 | $36.25 |
| AVG Volume (30 Days) | 440.9K | ★ 680.0K |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 2.34% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $97.60 | $8.61 |
| Revenue Next Year | $43.64 | $5.60 |
| P/E Ratio | ★ N/A | $64.97 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $124.06 | $23.91 |
| 52 Week High | $248.60 | $38.79 |
Technical Indicators
Market Signals| Indicator | ASND | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 53.82 | 39.60 |
| Support Level | $190.49 | $29.27 |
| Resistance Level | $233.88 | $32.61 |
| Average True Range (ATR) | 8.02 | 0.50 |
| MACD | 0.34 | -0.01 |
| Stochastic Oscillator | 66.05 | 40.04 |
Price Performance
Historical ComparisonAbout ASND Ascendis Pharma A/S
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.